Search Videos by Topic or Participant
Browse by Series:

PointBreak and AVAPERL Studies in NSCLC

Panelists: D. Ross Camidge, MD, PhD, University of Colorado;Ramaswamy Govindan, MD, Siteman; Roy S. Herbst, MD, PhD, Yale; Corey J. Langer, MD, Penn
Published: Saturday, Nov 29, 2014
For High-Definition, Click
Two recent clinical trials for patients with non-small cell lung cancer (NSCLC) demonstrated intriguing results for maintenance strategies with bevacizumab and pemetrexed.

The first, PointBreak, was a phase III randomized study looking at pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV non-squamous NSCLC. The second study, AVAPERL, was a phase III study that looked at bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced non-squamous NSCLC.

In the discussion, panelists discuss the findings from the AVAPERL and PointBreak studies. Additionally, they express optimism that ECOG-5508 will answer the lingering questions left by these studies. The phase III E5508 study is looking at maintenance therapy with bevacizumab, pemetrexed, or a combination of bevacizumab and pemetrexed following carboplatin, paclitaxel, and bevacizumab for advanced nonsquamous NSCLC.

View the video, to learn more!
Slider Left
Slider Right
For High-Definition, Click
Two recent clinical trials for patients with non-small cell lung cancer (NSCLC) demonstrated intriguing results for maintenance strategies with bevacizumab and pemetrexed.

The first, PointBreak, was a phase III randomized study looking at pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV non-squamous NSCLC. The second study, AVAPERL, was a phase III study that looked at bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced non-squamous NSCLC.

In the discussion, panelists discuss the findings from the AVAPERL and PointBreak studies. Additionally, they express optimism that ECOG-5508 will answer the lingering questions left by these studies. The phase III E5508 study is looking at maintenance therapy with bevacizumab, pemetrexed, or a combination of bevacizumab and pemetrexed following carboplatin, paclitaxel, and bevacizumab for advanced nonsquamous NSCLC.

View the video, to learn more!
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x